A case of Incontinentia Pigmenti associated with concurrent IKBKG/NEMO and MED13L mutations - Top-Institutions - MDSpire

A case of Incontinentia Pigmenti associated with concurrent IKBKG/NEMO and MED13L mutations

  • By

  • Ezia Spinosa

  • Jeremie Rosain

  • Stefania Picascia

  • Michele Salvia

  • Alessandra Pescatore

  • Annalaura Torella

  • Giulio Piluso

  • Vincenzo Nigro

  • Vincenzo Piccolo

  • Andrea Diociaiuti

  • Immacolata Di Biase

  • May El Hachem

  • Maria B. Lioi

  • Paul Bastard

  • Matilde V. Ursini

  • Francesca Fusco

  • June 18, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Incontinentia Pigmenti Genetic Biobank
    Incontinentia Pigmenti Genetic Biobank

    N/A, N/A

    Key Differentiators

    • Genetics

  • #2

    Incontinentia Pigmenti International Foundation
    Incontinentia Pigmenti International Foundation

    N/A, N/A

    Key Differentiators

    • Genetics

  • #3

    Italian Association of Incontinentia Pigmenti
    Italian Association of Incontinentia Pigmenti

    N/A, N/A

    Key Differentiators

    • Genetics

  • #4

    Federico II University
    Federico II University

    Naples, Italy

    Key Differentiators

    • Genetics

  • #5

    University of Tartu
    University of Tartu

    Tartu, Estonia

    Key Differentiators

    • Genetics

Original Source(s)

A case of Incontinentia Pigmenti associated with concurrent IKBKG/NEMO and MED13L mutations

  • by Ezia Spinosa, Jeremie Rosain, Stefania Picascia, Michele Salvia, Alessandra Pescatore, Annalaura Torella, Giulio Piluso, Vincenzo Nigro, Vincenzo Piccolo, Andrea Diociaiuti, Immacolata Di Biase, May El Hachem, Maria B. Lioi, Paul Bastard, Matilde V. Ursini, Francesca Fusco

  • June 18, 2026

Related Content

Clinical and dermoscopic analysis of 32 cases of acquired facial hyperpigmented macules

Correction: Exploring the role of ferroptosis in pemphigus: identification of diagnostic markers and regulatory mechanisms

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma